Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse

Joshua D. Lambert, Ross O. Meyers, Barbara N. Timmermann, Robert T Dorr

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Nordihydroguaiaretic acid (NDGA) has been shown to inhibit both 5-lipoxygenase and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model. Despite these findings, there have been no reports on the pharmacokinetics of NDGA. A reverse-phase high-performance liquid chromatography (HPLC) method was developed to detect NDGA in mouse plasma. The limit of detection of this method was 0.5 μg/ml. Administration of NDGA (50 mg/kg, i.v.) to mice resulted in a peak plasma concentration of 14.7 μg/ml. The terminal half-life of NDGA was 135.0 min with a clearance of 201.9 ml/min·kg.

Original languageEnglish (US)
Pages (from-to)85-90
Number of pages6
JournalJournal of Chromatography B: Biomedical Sciences and Applications
Volume754
Issue number1
DOIs
StatePublished - Apr 15 2001

Fingerprint

Masoprocol
Pharmacokinetics
High performance liquid chromatography
Plasmas
Arachidonate 5-Lipoxygenase
Ornithine Decarboxylase
Tumors
Cells

Keywords

  • Nordihydroguaiaretic acid

ASJC Scopus subject areas

  • Chemistry(all)

Cite this

Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse. / Lambert, Joshua D.; Meyers, Ross O.; Timmermann, Barbara N.; Dorr, Robert T.

In: Journal of Chromatography B: Biomedical Sciences and Applications, Vol. 754, No. 1, 15.04.2001, p. 85-90.

Research output: Contribution to journalArticle

@article{905e5e8fc6b04b7a8c7bb09661e0324c,
title = "Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse",
abstract = "Nordihydroguaiaretic acid (NDGA) has been shown to inhibit both 5-lipoxygenase and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model. Despite these findings, there have been no reports on the pharmacokinetics of NDGA. A reverse-phase high-performance liquid chromatography (HPLC) method was developed to detect NDGA in mouse plasma. The limit of detection of this method was 0.5 μg/ml. Administration of NDGA (50 mg/kg, i.v.) to mice resulted in a peak plasma concentration of 14.7 μg/ml. The terminal half-life of NDGA was 135.0 min with a clearance of 201.9 ml/min·kg.",
keywords = "Nordihydroguaiaretic acid",
author = "Lambert, {Joshua D.} and Meyers, {Ross O.} and Timmermann, {Barbara N.} and Dorr, {Robert T}",
year = "2001",
month = "4",
day = "15",
doi = "10.1016/S0378-4347(00)00592-2",
language = "English (US)",
volume = "754",
pages = "85--90",
journal = "Journal of Chromatography B: Biomedical Sciences and Applications",
issn = "0378-4347",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse

AU - Lambert, Joshua D.

AU - Meyers, Ross O.

AU - Timmermann, Barbara N.

AU - Dorr, Robert T

PY - 2001/4/15

Y1 - 2001/4/15

N2 - Nordihydroguaiaretic acid (NDGA) has been shown to inhibit both 5-lipoxygenase and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model. Despite these findings, there have been no reports on the pharmacokinetics of NDGA. A reverse-phase high-performance liquid chromatography (HPLC) method was developed to detect NDGA in mouse plasma. The limit of detection of this method was 0.5 μg/ml. Administration of NDGA (50 mg/kg, i.v.) to mice resulted in a peak plasma concentration of 14.7 μg/ml. The terminal half-life of NDGA was 135.0 min with a clearance of 201.9 ml/min·kg.

AB - Nordihydroguaiaretic acid (NDGA) has been shown to inhibit both 5-lipoxygenase and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model. Despite these findings, there have been no reports on the pharmacokinetics of NDGA. A reverse-phase high-performance liquid chromatography (HPLC) method was developed to detect NDGA in mouse plasma. The limit of detection of this method was 0.5 μg/ml. Administration of NDGA (50 mg/kg, i.v.) to mice resulted in a peak plasma concentration of 14.7 μg/ml. The terminal half-life of NDGA was 135.0 min with a clearance of 201.9 ml/min·kg.

KW - Nordihydroguaiaretic acid

UR - http://www.scopus.com/inward/record.url?scp=0035871898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035871898&partnerID=8YFLogxK

U2 - 10.1016/S0378-4347(00)00592-2

DO - 10.1016/S0378-4347(00)00592-2

M3 - Article

C2 - 11318430

AN - SCOPUS:0035871898

VL - 754

SP - 85

EP - 90

JO - Journal of Chromatography B: Biomedical Sciences and Applications

JF - Journal of Chromatography B: Biomedical Sciences and Applications

SN - 0378-4347

IS - 1

ER -